Cannabis less harmful than drinking, smoking: report

Cannabis is less harmful than alcohol or tobacco, according to a report by a British research charity Thursday, which called for a "serious rethink" of drug policy.

The Beckley Foundation, a charity which numbers senior British and other academics among its advisors, said banning cannabis has no impact on supply and turns users into criminals.

"Although cannabis can have a negative impact on health, including mental health, in terms of relative harms it is considerably less harmful than alcohol or tobacco," says the report by the Foundation's Global Cannabis Commission.

The British government is pressing for cannabis to be re-classified in law as a Class B drug compared with its current, less serious, Class C classification.

Authorities are concerned notably by the growing prevalence of the potent "skunk" form of the drug. Around 80 percent of cannabis seizures are of this strain, said to be linked to mental health problems, official figures show.

The Beckley Foundation, a charitable trust, claimed only two deaths worldwide have been attributed to cannabis, while alcohol and tobacco use together kill an estimated 150,000 people in Britain alone.

"Many of the harms associated with cannabis use are the result of prohibition itself, particularly the social harms arising from arrest and imprisonment," it said.

"It is only through a regulated market that we can better protect young people from the ever more potent forms of dope," it added.

The decision to reclassify cannabis upwards into the more punitive Class B category -- which includes amphetamines -- is a U-turn for Britain's Labour government.

Cannabis was downgraded from Class B when Tony Blair was prime minister, but Gordon Brown announced a review of its status soon after taking over in June last year.

An earlier review of the cannabis classification, at the time of the last 2005 general election, resulted in it remaining Class C.

© 2008 AFP

Related stories:

Despite failures, search for obesity drugs still looks golden
Designers of anti-obesity drugs have suffered three major setbacks, but the potential reward from treating the world's fat epidemic is so great that their quest is unlikely to be deterred.
New 'matrix of harm' for drugs of abuse
A new study published today in the Lancet proposes that drugs should be classified by the amount of harm that they do, rather than the sharp A, B, and C divisions in the UK Misuse of Drugs Act.
New study identifies links between musical tastes and lifestyle
The music we listen to can tell a lot more than you might think about what kind of people we are, according to research findings by a University of Leicester psychologist.
Alcohol and licensing policy could be changing the habits of young drinkers
In a new report published online today in the January issue of Addiction, researchers question whether current licensing policies have contributed to a rise in the phenomenon of "pre-drinking" amongst young people.
Researchers explore marijuana and mental health
(PhysOrg.com) -- A team of mental health experts from the University of Western Sydney say young people who have developed a dependence on cannabis are likely to continue using the drug following the diagnosis of a mental illness.
New cannabis-like drugs could block pain without affecting brain, says study
A new type of drug could alleviate pain in a similar way to cannabis without affecting the brain, according to a new study published in the journal Pain on Monday 15 September.
A Problem with Alcohol? Me? Not likely!
How young people end up in treatment for alcohol abuse could influence how successful that treatment is.
A mechanism for the development of obesity-associated conditions
Substances known as endocannabinoids have been implicated in the development of many effects of a high-fat diet, including risk factors for type 2 diabetes. New data have now indicated that these effects of endocannabinoids occur via activation of the protein CB1 in the liver and not the brain. Therefore, targeting liver CB1 might provide an effective way to treat obesity-related medical conditions without the side effects of targeting CB1 in the brain, anxiety and depression.

News discussion:

Medicine & Health news